PDF Cover

Cabotegravir Market

The market for Cabotegravir was estimated at $902 million in 2024; it is anticipated to increase to $1.46 billion by 2030, with projections indicating growth to around $2.17 billion by 2035.

Report ID:DS1802586
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Cabotegravir
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Cabotegravir Market Outlook

Revenue, 2024

$902M

Forecast, 2034

$2.00B

CAGR, 2025 - 2034

8.3%

The Cabotegravir industry revenue is expected to be around $977.3 million in 2025 and expected to showcase growth with 8.3% CAGR between 2025 and 2034. Building on this anticipated growth trajectory, the cabotegravir market is gaining strong clinical and commercial significance as global healthcare systems intensify efforts to control and prevent HIV infections. Increasing awareness of pre-exposure prophylaxis and the need for long-acting therapeutic options are key factors driving adoption. Healthcare providers are prioritizing treatment regimens that improve patient adherence, particularly in populations where daily oral therapies present challenges. Additionally, supportive government initiatives and global health programs aimed at reducing HIV transmission are reinforcing demand. Strategic collaborations between pharmaceutical companies and public health organizations are further expanding access in emerging markets, strengthening the drug’s role in long-term HIV management and prevention strategies.

Cabotegravir is a long-acting integrase strand transfer inhibitor used for both HIV treatment and prevention. It is commonly administered as an injectable formulation, either as part of combination therapy for HIV-positive patients or as a preventive option for at-risk populations. Its extended dosing interval, typically administered monthly or less frequently, offers a significant advantage over daily oral medications by enhancing adherence and convenience. Key applications include HIV pre-exposure prophylaxis and maintenance therapy in virologically suppressed patients. Recent trends highlight increasing adoption of long-acting antiretroviral therapies, expansion of access programs in developing regions, and ongoing clinical research to broaden indications and optimize dosing strategies.

Cabotegravir market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Cabotegravir Market Outlook

Market Key Insights

  • The Cabotegravir market is projected to grow from $902.4 million in 2024 to $2.00 billion in 2034. This represents a CAGR of 8.3%, reflecting rising demand across HIV Treatment, Prophylaxis of HIV-1 Infection, and Treatment of Drug-Resistant HIV.

  • ViiV Healthcare, GlaxoSmithKline plc, Pfizer Inc. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and UK are the top markets within the Cabotegravir market and are expected to observe the growth CAGR of 6.1% to 8.7% between 2024 and 2030.

  • Emerging markets including Brazil, South Africa and Indonesia are expected to observe highest growth with CAGR ranging between 8.0% to 10.4%.

  • Transition like Shift from daily oral antiretrovirals to long-acting injectable HIV therapies is expected to add $148 million to the Cabotegravir market growth by 2030.

  • The Cabotegravir market is set to add $1.1 billion between 2024 and 2034, with manufacturer targeting Government Health Agencies & Medical Research Institutions Application projected to gain a larger market share.

  • With

    rising hiv infections, and

    Technological Advancements in Antiretroviral Therapy, Cabotegravir market to expand 122% between 2024 and 2034.

cabotegravir market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Cabotegravir - Country Share Analysis

Opportunities in the Cabotegravir

The expansion of injectable pre-exposure prophylaxis programs in sub-Saharan Africa represents a major opportunity for cabotegravir, particularly among high-risk populations. This region accounts for a significant share of new HIV infections, creating strong demand for long-acting preventive therapies. Public health partnerships and global funding initiatives are enabling large-scale rollout of injectable PrEP, improving access in underserved communities. Long-acting injectable cabotegravir is also expected to see the highest growth in this segment, as it addresses adherence challenges associated with daily oral regimens and integrates effectively into community-based healthcare delivery models.

Growth Opportunities in North America and Europe

Cabotegravir is gaining strong traction in North America, driven by high HIV awareness, favorable reimbursement frameworks, and rapid integration into sexual health clinics. The region leads global uptake of long-acting injectable PrEP, supported by clinical evidence showing superior efficacy and adherence versus daily oral regimens. Top opportunities lie in expanding access among underserved populations, including women and minority groups, and scaling public health programs targeting adherence challenges. Competition is intensifying from oral PrEP generics and emerging long-acting agents like lenacapavir. Key drivers include government-backed HIV prevention initiatives, strong healthcare infrastructure, and growing preference for bi-monthly injectable therapies that reduce pill burden and improve compliance.
Europe represents a steadily expanding market for cabotegravir, supported by regulatory approvals and increasing reimbursement across countries like the UK and Scotland. Growth is driven by robust public healthcare systems, national HIV elimination strategies, and rising adoption of long-acting injectables to improve adherence. Key opportunities include broader PrEP penetration in Western Europe and expansion into underserved Eastern regions. However, competition from established antiretroviral therapies and pricing pressure from generics remain challenges. Market drivers include strong policy support, increasing awareness, and a shift toward simplified, long-acting HIV prevention regimens.

Market Dynamics and Supply Chain

01

Driver: Increasing global HIV prevention initiatives alongside growing demand for long-acting therapies

The expansion of global HIV prevention programs is also a major driver for cabotegravir, as governments and health organizations intensify efforts to reduce transmission rates. Large-scale awareness campaigns and funding support are also improving access to preventive treatments, particularly in high-burden regions. At the same time, there is also a strong shift toward long-acting therapies that address adherence challenges associated with daily oral regimens. Cabotegravir’s extended dosing intervals offer a practical solution, especially for populations with inconsistent healthcare access. This dual trend of preventive focus and long-acting treatment preference is also accelerating adoption, as healthcare systems prioritize effective, patient-friendly solutions that enhance compliance and deliver sustained protection against HIV infection.
Continuous innovation in injectable drug delivery systems is also significantly boosting the adoption of cabotegravir in HIV treatment and prevention. Long-acting intramuscular formulations enable controlled drug release over extended periods, reducing dosing frequency and improving patient convenience. This advancement is also particularly impactful in managing chronic conditions like HIV, where adherence directly influences treatment success. Additionally, healthcare providers are also increasingly favoring injectable regimens for their ability to ensure consistent therapeutic levels and reduce the risk of missed doses. These innovations are also expanding clinical acceptance and supporting broader integration of cabotegravir into modern antiretroviral therapy protocols.
02

Restraint: High treatment costs and reimbursement limitations restricting widespread patient access globally

The high acquisition and administration cost of cabotegravir remains a critical restraint, particularly when compared to lower-cost generic oral antiretroviral therapies. Economic evaluations indicate that long-acting cabotegravir is more expensive overall, creating budgetary pressure for healthcare systems and payers. Additionally, complex reimbursement negotiations in regions such as Europe have delayed or restricted access, with some countries limiting use to select high-risk populations. This directly impacts market revenue by narrowing the eligible patient pool and slowing adoption rates. In cost-sensitive markets, healthcare providers often prioritize established, affordable therapies, reducing demand growth and creating uneven global penetration despite strong clinical benefits.
03

Opportunity: Generic licensing partnerships expanding access in low and middle income countries and Development of ultra long acting formulations enabling extended dosing intervals globally

Strategic licensing agreements allowing generic production of cabotegravir are unlocking new opportunities in low and middle income countries. Pharmaceutical companies are collaborating with global health organizations to expand affordable access, particularly for HIV treatment and prevention programs. These partnerships enable local manufacturers to produce cost-effective versions, significantly increasing market penetration in price-sensitive regions. The combination injectable therapy segment is expected to grow the most, supported by inclusion in national HIV treatment guidelines. This trend is reshaping demand dynamics by expanding the patient base while reducing cost barriers across emerging healthcare systems.
Ongoing innovation in ultra long-acting formulations is creating a strong growth opportunity for cabotegravir in both treatment and prevention segments. New formulations under development aim to extend dosing intervals from monthly to every few months, improving patient convenience and adherence. This advancement is particularly valuable in chronic HIV management, where reducing clinic visits enhances patient retention. Long-acting injectable formulations are expected to dominate growth, especially in developed markets with advanced healthcare infrastructure. This trend is also encouraging broader adoption among patients seeking simplified, low-frequency treatment options, strengthening long-term market expansion.
04

Challenge: Logistical challenges and adherence barriers associated with injectable dosing schedules

Despite its long-acting advantage, cabotegravir faces operational challenges related to its injectable delivery model. Patients must adhere to strict clinic visit schedules for periodic injections, creating logistical burdens for both healthcare systems and users. Missed appointments can compromise treatment effectiveness and increase the risk of resistance, influencing physician prescribing behavior. Furthermore, real-world rollout has been slow due to limited healthcare infrastructure and access constraints, particularly in developing regions. These factors reduce patient uptake and limit scalability, especially outside controlled clinical settings. As a result, demand growth is moderated, with adoption largely concentrated in well-equipped healthcare systems capable of supporting consistent administration.

Supply Chain Landscape

1

Raw Material Procurement

Sigma-AldrichBASF AG
2

API Production

Pfizer IncRoche AG
3

Drug Formulation & Production

ViiV HealthcareGlaxoSmithKline plc
4

Distribution & End Users

Pharmaceutical wholesalersHospital PharmaciesRetail Pharmacies
Cabotegravir - Supply Chain

Use Cases of Cabotegravir in HIV Treatment & Prophylaxis of HIV-1 Infection

HIV Treatment : Cabotegravir is increasingly used in HIV treatment as part of long-acting injectable regimens designed to improve patient adherence and treatment outcomes. The long-acting intramuscular injectable form, often used in combination therapy, is most commonly adopted in this segment. It is administered monthly or at extended intervals, reducing the burden of daily oral medication. This approach is particularly beneficial for patients with adherence challenges or those seeking more convenient treatment options. Its ability to maintain consistent drug levels enhances viral suppression, making it a preferred option in maintenance therapy for virologically stable patients under clinical supervision.
Prophylaxis of HIV-1 Infection : In the prophylaxis of HIV-1 infection, cabotegravir is widely used as a long-acting injectable for pre-exposure prophylaxis in high-risk populations. This application primarily utilizes extended-release injectable formulations administered every few months, offering a significant advantage over daily oral prophylactic drugs. It is particularly effective for individuals with inconsistent adherence to oral regimens, including vulnerable and mobile populations. The reduced dosing frequency improves compliance and overall effectiveness in preventing HIV transmission. Increasing public health initiatives and awareness campaigns are driving adoption, especially in regions with high infection rates and limited access to continuous healthcare services.
Treatment of Drug-Resistant HIV : Cabotegravir is also gaining relevance in the treatment of drug-resistant HIV, where traditional antiretroviral therapies may be less effective. In this application, the long-acting injectable form is used as part of combination regimens tailored to overcome resistance challenges. Its mechanism as an integrase inhibitor allows it to target viral replication differently, providing an effective alternative in complex treatment cases. This approach is particularly valuable in specialized care settings where personalized treatment plans are required. The growing incidence of drug resistance and the need for advanced therapeutic options are supporting increased adoption, especially in developed healthcare markets with access to specialized treatments.

Recent Developments

Recent developments in cabotegravir (CAB-LA) highlight strong momentum in long-acting HIV prevention, with regulatory expansion and real-world rollout accelerating uptake. In 2025, NICE-backed adoption and NHS rollout reinforced its role as a bi-monthly injectable PrEP alternative, improving adherence versus daily oral regimens . Clinical and implementation studies show high acceptability, >95% adherence, and strong uptake among previously untreated populations . A key market trend is intensifying competition from ultra-long-acting agents like lenacapavir, alongside upcoming generics and access-focused licensing, shaping pricing and accessibility dynamics

February 2026 : ViiV Healthcare reported Phase III LATITUDE trial results showing its cabotegravir-based long-acting injectable significantly reduced virological failure versus daily oral therapy, with findings published in NEJM
February 2026 : ViiV Healthcare presented IMPAACT 2017 (MOCHA) study data at CROI 2026 demonstrating >94% viral suppression in adolescents using long-acting cabotegravir + rilpivirine, expanding clinical use in younger populations

Impact of Industry Transitions on the Cabotegravir Market

As a core segment of the Pharmaceutical industry, the Cabotegravir market develops in line with broader industry shifts. Over recent years, transitions such as Shift from daily oral antiretrovirals to long-acting injectable HIV therapies and Transition from treatment-focused approaches to integrated prevention and management strategies have redefined priorities across the Pharmaceutical sector, influencing how the Cabotegravir market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift from daily oral antiretrovirals to long-acting injectable HIV therapies

The cabotegravir market is undergoing a significant transition from traditional daily oral antiretroviral regimens to long-acting injectable therapies. This shift is driven by the need to improve patient adherence and reduce the burden of daily medication. For example, healthcare providers are increasingly prescribing injectable regimens for both HIV treatment and prevention, particularly among populations with adherence challenges. This transition is reshaping pharmaceutical strategies, with companies focusing on long-acting drug pipelines. It is also influencing healthcare delivery models, as clinics adapt to scheduled injection-based care rather than routine prescription refills.
02

Transition from treatment-focused approaches to integrated prevention and management strategies

Another key transition is the movement from purely treatment-oriented HIV care to integrated prevention and management frameworks. Cabotegravir is increasingly used not only for treating HIV-positive patients but also for pre-exposure prophylaxis in high-risk populations. For instance, public health programs are incorporating injectable PrEP into broader HIV prevention strategies, expanding the drug’s application scope. This transition is driving collaboration between governments, NGOs, and pharmaceutical companies, while also shifting funding priorities toward preventive care. It is strengthening demand across both clinical and community healthcare settings, reshaping the overall HIV therapeutics landscape.